Metabolomic Profiling in Neuromyelitis Optica Spectrum Disorder Biomarker Discovery

Area of Science:

• Neuroimmunology
• Biomarker Discovery
• Metabolomics

Background:

• Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune central nervous system disease.
• Current NMOSD diagnosis lacks specific tests, relying on differential diagnosis, leading to treatment delays and misdiagnosis.
• Pathogenic autoantibodies against aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein (MOG) are key in NMOSD.

Purpose of the Study:

• To identify reliable biomarkers for early and accurate diagnosis of NMOSD.
• To differentiate between NMOSD subtypes (AQP4-Ab+, MOG-Ab+, and double-negative) and related disorders.
• To analyze metabolomic and proteomic data for NMOSD diagnostic candidates.

Main Methods:

• Comprehensive data collection and analysis of metabolomic perturbations in NMOSD.
• Integration of related proteomic outcomes.
• Identification of candidate biomarkers from metabolic profiles.

Main Results:

• Short chain fatty acids, lipoproteins, amino acids, and lactate are highlighted as potential diagnostic biomarkers for NMOSD.
• Metabolomic profiling shows promise for individual NMOSD patient care.
• The study provides a foundation for understanding NMOSD's metabolic landscape.

Conclusions:

• Early and accurate diagnosis of NMOSD is critical to prevent treatment-related adverse events and improve prognosis.
• Metabolomic profiling offers a promising avenue for developing specific NMOSD diagnostic tools.
• Further research is essential to validate these candidate biomarkers and integrate metabolomic profiling into clinical practice.